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ABSTRACT
Follicular lymphoma (FL) is a heterogeneous disease with vary-
ing prognosis owing to differences in clinical, laboratory, and
disease parameters. Although generally considered incurable,
prognosis for early- and advanced-stage disease has improved
because of therapeutic advances, several of which have
resulted from elucidation of the biologic and molecular basis of
the disease. The choice of treatment for FL is highly dependent
on patient and disease characteristics. Several tools are avail-
able for risk stratiﬁcation, although limitations in their routine
clinical use exist. For limited disease, treatment options include
radiotherapy, rituximab monotherapy or combination regi-
mens, and surveillance. Treatment of advanced disease is often
determined by tumor burden, with surveillance or rituximab
considered for low tumor burden and chemoimmunotherapy
for high tumor burden disease. Treatment for relapsed or
refractory disease is inﬂuenced by initial ﬁrst-line therapy and
the duration and quality of the response. Presently, there is no
consensus for treatment of patients with early or multiply
relapsed disease; however, numerous agents, combination reg-
imens, and transplant options have demonstrated efﬁcacy.
Although the number of therapies available to treat FL has
increased together with an improved understanding of the
underlying biologic basis of disease, the best approach to select
the most appropriate treatment strategy for an individual
patient at a particular time continues to be elucidated. This
review considers prognostication and the evolving treatment
landscape of FL, including recent and emergent therapies as
well as remaining unmet needs. The Oncologist 2019;24:1–15
Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient
characteristics, and other factors continues to emerge. However, application of current management requires an under-
standing of the available therapeutic options for ﬁrst-line treatment and knowledge of current development in therapies for
previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in
follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies.
INTRODUCTION
Follicular lymphoma (FL) is the most common indolent non-
Hodgkin lymphoma (NHL) in Western countries, with an
annual incidence of 3.4–5 per 100,000 in Europe and the
U.S. [1, 2]. Median age of diagnosis is 65 years [3], but a
large proportion of cases also occurs in younger adults [4].
Although incurable, prognosis has improved for early- and
advanced-stage disease, largely attributed to therapeutic
advances.
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FL is a heterogeneous disease with varying prognosis,
inﬂuenced by differences in clinical, laboratory, and disease
parameters between patients. Spontaneous regressions might
occur in about 5%–10% of patients [5]. Although many patients
can be initially observed, most require therapy after a median
of 3–4 years after diagnosis [6]. Approximately 20% of patients
will have early relapse within 2 years following current ﬁrst-line
therapy [7]. Thus, FL has a typically protracted course, withmul-
tiple remissions and relapses.
Although continued elucidation of the biologic and molecu-
lar basis of FL is leading to identiﬁcation of new potential ther-
apeutic avenues, the heterogeneity of FL presents challenges,
including selection of appropriate management for individual
patients. This review considers prognostic approaches and the
FL treatment landscape, including recent and emergent thera-
pies and remaining unmet needs.
PATHOBIOLOGICAL HETEROGENEITY
The World Health Organization (WHO) FL grading system is
formed on the basis of differing proportions of centroblasts per
high-powered ﬁeld, with a greater proportion indicative of a
more aggressive phenotype [8]. Grades 1–2 and 3A are consid-
ered histologically low-grade and indolent disease [9], whereas
grade 3B is considered biologically distinct from grades 1–3A [10,
11] and typically treated as an aggressive lymphoma [2, 12].
However, it is important to note that centers largely group grades
1–3A as low-grade lymphoma given inter- and even intraobserver
variability in scoring grade, whereas grade 3B remains a routinely
distinguishable pathologic entity characterized by sheets of
immunoblasts. Further highlighting the histologic heterogeneity,
the 2016 WHO classiﬁcation update includes entities (e.g., duo-
denal-type disease) [13] that are distinguished from nodal FL by
different immune-microenvironment proﬁles [14].
FL transformation from an indolent to more aggressive
disease is a well-recognized complication during the natural
disease history. Transformation is deﬁned by histologic evi-
dence of diffuse large B-cell lymphoma (DLBCL) or other high-
grade morphology, usually accompanied by rapid progression
of lymphadenopathy, extranodal disease outside the marrow,
B symptoms, elevated serum lactate dehydrogenase, and, less
commonly, hypercalcemia [15]. Histologic-transformation risk
has historically been reported in 3% of patients annually [16,
17] but is believed to be lower in the rituximab era [18–20].
An extensive catalog of genetic changes occurring in FL is
available. An unexpected revelation was the high prevalence
of mutations in genes encoding proteins regulating the
epigenome through speciﬁc histone post-translational modiﬁ-
cations (KMT2D, CREBBP, EP300, EZH2) [21–24]. Mutations in
genes involved in cellular processes such as JAK-STAT, BCR-
NFkB, mTOR signal transduction, cell-cycle regulation,
immune modulation, and cellular differentiation are also fre-
quent [23–27], several of which are potential therapeutic tar-
gets and some of which are prognostically relevant [25, 28].
Furthermore, genetic proﬁles of FL tumors can evolve longi-
tudinally over the disease course [23, 24, 29–31] and spatially
within tumors at different sites of involvement [32].
In addition to genetic alterations, tumor cells exist
within a milieu of nonmalignant cells making up the micro-
environment, which is pivotal in contributing to disease
development, maintenance, and progression. A seminal
study identiﬁed that gene expression signatures derived
from nonmalignant immune cells (T cells vs. macrophages)
independently predicted clinical outcome in FL, underpin-
ning the critical role of the tumor microenvironment [33]. It
is envisaged that building a more in-depth understanding of
the biological basis of FL will inform newer approaches to
targeting these tumors.
RISK STRATIFICATION
Recent data suggest the strongest predictor of long-term FL
outcomes is length of ﬁrst remission after front-line ther-
apy. Patients with progression of disease within 24 months
of completing induction chemoimmunotherapy (POD24),
which made up 19% of patients in this data set, had poorer
outcomes compared with those with longer remission dura-
tions (5-year overall survival [OS]: 50% vs. 90%, respec-
tively) even after adjustment for Follicular Lymphoma
International Prognostic Index (FLIPI) score (discussed
below) [7]. These results were validated in the University of
Iowa and Mayo Clinic Molecular Epidemiology Resource data
sets [7], and in the GALLIUM study and using the FLASH data
set [34, 35]. Additionally, a longer duration from diagnosis to
progression (i.e., event-free survival of >12 months after
diagnosis) did not result in excess mortality compared with
the age- and sex-matched general population [36].
Based on retrospective survival data from patients
diagnosed in the preimmunotherapy era, the FLIPI consists
of ﬁve clinical parameters and categorizes patients into
one of three risk groups (Table 1) [37]. The FLIPI has been
validated in clinical trials of chemoimmunotherapy and in
the National LymphoCare study observational cohort and
was validated using OS and progression-free survival (PFS)
in the prechemoimmunotherapy era [38, 39]. FLIPI-2 was
subsequently developed as a more contemporary prognos-
tic model using data reﬂective of treatment in the
chemoimmunotherapy era [40]. It includes bone marrow
involvement, nodal diameter, and β2-microglobulin levels
and was built on PFS in chemoimmunotherapy-treated
patients. A streamlined index has been proposed, the
PRIMA-PI, which uses a simpliﬁed algorithm of bone mar-
row involvement and β2-microglobulin level to predict PFS
[41]. Other tools to predict outcome in FL have been pro-
posed, including total metabolic tumor volume (TMTV) as
determined from baseline positron emission tomography
(PET) [42], combining FLIPI-2 with TMTV [43], and assess-
ment of the presence of circulating peripheral blood lym-
phoma cells [44].
The m7-FLIPI, a clinicogenetic risk score derived from a
combination of the mutation status of seven candidate
genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP,
CARD11) together with clinical parameters (FLIPI score and
Eastern Cooperative Oncology Group performance status)
stratiﬁes patients into a low-risk group (78% of patients)
with a 5-year failure-free survival of 68% versus 25% in a
high-risk group (22% of patients) [45]. m7-FLIPI was used to
identify patients at risk of early relapse (POD24) using data
from the German Low-Grade Lymphoma Study Group trial
and the British Columbia Cancer Agency population-based
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registry [46]. They conﬁrmed that 5-year OS of patients
with POD24 was signiﬁcantly worse than that of patients
without POD24 (26%–41% vs. 86%–91%, respectively;
p < .0001) and that the m7-FLIPI had a higher accuracy in
predicting POD24 compared with FLIPI. Recently, a 23-gene
expression-based prognostic tool was developed that again
segregates patients into a low-risk (5-year PFS 73%) and
high-risk group (5-year PFS 26%) [47]. Both of these tools
were established and validated in retrospective cohorts of
patients with FL with symptomatic, advanced stage, grade
1–3A disease requiring systemic ﬁrst-line therapy (commonly
chemotherapy plus rituximab) [45, 47].
Metabolic responses to therapy have also been considered
as a means of predicting subsequent outcomes in FL [7, 34,
48–53]. For instance, end-of-induction PET was shown to be
prognostic after ﬁrst-line FL therapy, correlating with outcome
in prospective trials, retrospective analyses of prospective tri-
als, and pooled analyses [49–51].
Metabolic responses to therapy have also been
considered as a means of predicting subsequent
outcomes in FL. For instance, end-of-induction PET
was shown to be prognostic after first-line FL therapy,
correlating with outcome in prospective trials, retro-
spective analyses of prospective trials, and pooled
analyses.
Choice of FL treatment is highly individualized, depen-
dent on extent, burden, and progression of disease and
associated symptoms; treatment decisions currently cannot
be driven by available prognostic models, and work in this
ﬁeld is currently active. Although the current risk stratiﬁca-
tion models are predictive of outcomes, they do not have
sufﬁcient sensitivity or speciﬁcity to guide decision making
and remain primarily research tools that are being exam-
ined in prospective clinical trials
FL TREATMENT
Newly Diagnosed Disease
Assessment of a patient newly diagnosed with FL includes con-
sideration of disease burden, lymphoma-related symptoms,
presence of comorbidities, patient preference, and age. Newly
diagnosed FL can be broadly classiﬁed as limited or advanced-
stage disease and further classiﬁed according to degree of tumor
burden; choice ofmanagement varies accordingly (Fig. 1).
Localized/Limited-Stage Disease
Approximately 10%–15% of patients with FL have limited,
nonbulky disease at diagnosis, which includes Ann Arbor
stage I–II disease [2]. For Ann Arbor stage I or II (possibly con-
ﬁrmed by ﬂuorodeoxyglucose-PET) disease, use of 24-Gy
involved-ﬁeld radiotherapy (IFRT) administered in 12 fractions
is potentially curative and is often the preferred treatment
option for disease encompassed in a single appropriate radia-
tion port, with no additional apparent efﬁcacy beneﬁt of
higher doses [2, 12, 54]. By restricting the radiation ﬁeld size
to smaller volumes, IFRT limits radiation exposure to adjacent
uninvolved tissue, thereby reducing risk of long-term adverse
effects [12]. A recent assessment of outcomes of deﬁnitive
IFRT found that local relapses in or near irradiated ﬁelds are
rare, and the vast majority of failures are distant [55]. Addi-
tionally, only about 25% of patients experience grade 1/2
and <1% have grade 3 toxicities. For palliation and local con-
trol alone, two fractions of 2 Gy may be sufﬁcient [2, 56].
Based on experience in advanced disease, patients with
mildly symptomatic, localized disease have been treated with
rituximab monotherapy [2, 12], but this strategy should only
be used if radiotherapy cannot be safely administered. Differ-
ent rituximab treatment strategies (alone, in combination with
chemotherapy, or together with radiation therapy) and com-
parison with radiotherapy alone in limited disease have been
reported [57, 58]. Although combined modality approaches
improved PFS compared with radiotherapy alone, no OS differ-
ence between treatment approaches was seen. Additionally,
extrapolation from the experience in advanced-stage disease,
Table 1. Currently used clinical prognostic models for follicular lymphoma
Model Criteria Risk stratiﬁcation Prognosis
FLIPI [37, 39] 1. Age: >60 years
2. Ann Arbor Stage: III–IV
3. Hb concentration: <12 g/dL
4. Number of nodal sites: >4
5. Serum LDH concentration: >normal
Low: 0–1 risk factors 2-year OS: 98%; 2-year PFS: 84%
Intermediate: 2 risk factors 2-year OS: 94%; 2-year PFS: 72%
High: 3–5 risk factors 2-year OS: 87%; 2-year PFS: 65%
FLIPI-2 [40] 1. Age: >60 years
2. Bone marrow involvement: yes
3. Hb concentration: <12 g/dL
4. Greatest diameter of largest involved
node: >6 cm
5. Serum β2 microglobulin concentration: >ULN
Low: 0–1 risk factors 3-year PFS: 91%
Intermediate: 2 risk factors 3-year PFS: 69%
High: 3–5 risk factors 3-year PFS: 51%
GELF [60] 1. Tumor size: any site >7 cm or ≥ 3 sites >3 cm
2. B symptoms: yes
3. Spleen: below umbilical line
4. Compressive symptoms: yes
5. Pleural or peritoneal effusion: yes
6. Leukemic phase >5 × 109/L
7. Neutropenia (<1 × 109/L) or thrombocytopenia
(<100 × 109/L) due to disease
High tumor burden:
≥1 risk factors
Abbreviations: FLIPI, Follicular Lymphoma International Prognostic Index; GELF, Groupe d’Etude des Lymphomes Folliculaires; Hb, hemoglobin;
LDH, lactate dehydrogenase; OS, overall survival; PFS, progression-free survival; ULN, upper limit of normal.
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in which surveillance is standard, has been used as a rationale
to support use of surveillance for management of limited-stage
disease in selected patients [59].
Advanced Disease
Patients with advanced disease may be symptomatic or asymp-
tomatic at diagnosis, and not all require immediate therapy.
The Groupe d’Etude des Lymphomes Folliculaires criteria,
which include tumor burden and clinical parameters, offer
guidance for when treatment should be initiated (Table 1) [60].
Surveillance is routinely favored for advanced disease, with
therapy typically reserved for patients with symptoms from or
signiﬁcant burden or rapid pace of disease [2]. For advanced
disease but low tumor burden and no disease-related symp-
toms, surveillance or rituximab monotherapy may be consid-
ered front-line therapy [2, 12]. Rituximab monotherapy is a
relevant consideration for such patients, particularly those
who are frail and unsuitable for chemoimmunotherapy, as a
notable proportion of patients (30%) with symptomatic,
advanced disease treated with rituximab alone may not need
further therapy for >10 years [20].
Studies have assessed the beneﬁt of immediate rituximab
treatment versus surveillance in asymptomatic, advanced-
stage disease [5, 20]. The largest showed a predictable PFS
beneﬁt of immediate rituximab therapy versus observation
but no OS difference [5]. Additionally, the RESORT trial com-
pared an extended rituximab schedule (four weekly doses
followed by a single dose every 3 months until treatment fail-
ure) with a retreatment schedule (four weekly doses followed
by retreatment at each disease progression) in stage III/IV and
low tumor burden FL [61]. The retreatment strategy provided
comparable disease control and delay of need for cytotoxic
chemotherapy comparable to the extended schedule (median
time to treatment failure: 3.9 vs. 4.3 years) and required
cumulatively fewer rituximab doses, the latter of which is
anticipated to result in beneﬁts to the patient and health care
system in terms of decreased direct and indirect costs. Impor-
tantly, this approach should only be used for patients with
advanced stage but low tumor burden and not for patients
who are candidates for chemoimmunotherapy.
Current standard of care (SOC) for advanced FL with high
disease burden is chemoimmunotherapy regimens that include
a CD20 antibody (e.g., rituximab, obinutuzumab) [2]. The addi-
tion of rituximab to combination chemotherapy regimens has
resulted in improvement in clinical outcomes including objec-
tive response rates (ORR), complete responses (CR), time-to-
progression, and OS in untreated, advanced-stage FL compared
with chemotherapy alone [62–69]. Additionally, the 10-year
follow-up of the PRIMA study showed that 2 years of rituximab
maintenance therapy after ﬁrst-line chemoimmunotherapy sig-
niﬁcantly improved PFS and >50% of patients did not require
second-line treatment 10 years after chemoimmunotherapy
[70, 71]. However, there continues to be no difference in OS
withmaintenance rituximab in this setting. Although these regi-
mens remain SOC for ﬁrst-line FL therapy, no randomized stud-
ies have shown OS superiority of a particular chemotherapy
backbone among the available options; however, the safety
proﬁles differ between regimens [67, 72–74]. For instance, the
StiL and BRIGHT trials showed that a bendamustine backbone
is as effective as rituximab, cyclophosphamide, doxorubicin, vin-
cristine, prednisone (R-CHOP) and has a better-tolerated side-
effect proﬁle especially with regard to hematological toxicities
and infection rates [72, 73]. However, although bendamustine
is favored as the chemotherapy backbone by many, there con-
tinues to be some variability in clinical practice [75, 76].
Obinutuzumab is a glycoengineered anti-CD20 monoclonal
antibody that has greater antibody-dependent cellular toxicity
and direct B-cell killing compared with rituximab [77]. First-line
obinuzutuzumab in combination with chemotherapy was
reported in the phase III GALLIUM study in indolent FL or
Treatment naive
Limited disease*
Advanced disease
Low tumor burden
High tumor burden
Radiotherapy
Surveillance
Rituximab (alone or in combination 
with chemotherapy† or radiotherapy)
Surveillance
Rituximab†
Chemoimmunotherapy (that includes 
a CD20 antibody)†
Rituximab + lenalidomide
Rituximab‡
Figure 1. Treatment options in newly diagnosed follicular lymphoma. *Patients with limited disease but high tumor burden should be
treated as per patients with advanced disease and high tumor burden. †With or without anti-CD20 maintenance therapy. ‡For frail patients.
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marginal zone lymphoma [78]. Patients were randomized to
induction treatment with obinutuzumab-based or rituximab-
based chemotherapy (cyclophosphamide, doxorubicin, vincris-
tine, and prednisone [CHOP], cyclophosphamide, vincristine,
prednisone [CVP], or bendamustine), and responding patients
received ≤2 years of maintenance treatment with the same
anti-CD20 antibody received during induction. An improve-
ment in 3-year PFS was observed with obtinuzumab-based
therapy (80% vs. 73%; p = .001), with no difference in 3-year
OS. Post hoc analysis suggested that greater PFS beneﬁt was
seen in intermediate or high versus low FLIPI disease. ORR at
the end of induction was similar in the two groups (89% vs.
87%), with PFS curves separating during maintenance therapy.
Notably, obinutuzumab was associated with higher rates of infu-
sion reactions (59% vs. 49%). Additionally, the side-effect proﬁle
varied by chemotherapy regimen and treatment phase;
bendamustine was associated with higher grade 3–5 infection
and second neoplasm rates during maintenance treatment, and
CHOP with higher grade 3–5 neutropenia rates during induction.
Recently, results of the RELEVANCE trial in advanced,
untreated FL indicated similar efﬁcacy with rituximab plus
lenalidomide (an immunomodulatory agent) compared with
rituximab plus chemotherapy [79]. As a primary objective of
this study, superiority of lenalidomide in combination with
rituximab versus rituximab-based chemoimmunotherapy was
not demonstrated (interim 3-year PFS: 77% vs. 78%). More-
over, higher rates of grade 3/4 neutropenia (50% vs. 32%)
and cutaneous reactions (7% vs. 1%) were observed in the
lenalidomide-containing arms. However, these results sup-
port consideration of rituximab and lenalidomide as a rele-
vant ﬁrst-line therapeutic option for select patients.
Relapsed/Refractory Disease
Even with therapeutic advances, FL remains largely characterized
by multiple recurrences. Successive treatment lines will often be
required in the disease course, and the choice of each treatment
(Fig. 2) should aim to achieve disease control, promote quality
of life (QoL), and minimize treatment-related toxicity.
Later and Multiply Relapsed Disease
Treatment of FL relapse or progression depends in part upon
duration of remission with previous treatments [2, 12]. For
patients with relapse or progression on ﬁrst-line treatment
who have a longer duration of remission, options can include
chemoimmunotherapy followed by rituximab maintenance.
Obinutuzumab in combination with bendamustine followed
by obinutuzumab maintenance is also available for patients with
rituximab-refractory FL [80, 81]. Approval in this setting is based
on the phase III GADOLIN trial of obinutuzumab plus
bendamustine versus bendamustine alone in patients with CD20
+ indolent NHL refractory to rituximab [82]. PFS was signiﬁcantly
longer with combination therapy than with bendamustine mon-
otherapy (25.8 vs. 14.1 months; hazard ratio [HR] = 0.57;
p < .001), as was OS (HR = 0.67; p = .027) [83]. Obinutuzumab in
combination with bendamustine represents a validated strategy
for rituximab-refractory patients not previously treated with
Relapsed or 
refractory disease
Later and multiply 
relapsed
HSCT
PI3K inhibitors 
(idelalisib, copanlisib, duvelisib)
Lenalidomide + rituximab
Radio-immunotherapy
Chemoimmunotherapy followed by 
rituximab maintenance
PI3K inhibitors 
(idelalisib, copanlisib, duvelisib)
Obinutuzumab + bendamustine followed 
by obinutuzumab maintenance
Lenalidomide + rituximab
Radioimmunotherapy
Radiotherapy
for localized disease 
Radiotherapy
for localized disease 
Early relapse
Figure 2. Treatment options in relapsed or refractory follicular lymphoma.
Abbreviation: HSCT, hematopoietic stem cell transplant.
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either agent; however, given the increased use of bendamustine
as ﬁrst-line therapy, this option may be relevant to only a small
patient subset.
The oral PI3K-δ inhibitor idelalisib is included in treatment
guidelines as a second-line treatment option in relapsed/
refractory FL [12, 84], although U.S. approval is for relapsed FL
in patients who have received ≥2 prior systemic therapies [84].
Importantly, idelalisib in combination regimens has been asso-
ciated with increased risk of serious and potentially fatal
adverse events (AEs) such as colitis or pneumonitis. This led to
early halting of several phase III clinical trials and a low clinical
uptake of idelalisib [85].
Copanlisib is an intravenously administered pan-class I
PI3K inhibitor with higher potency against all class I isoforms
than other clinically investigated PI3K inhibitors and speciﬁ-
cally with heightened activity against the α and δ isoforms
[86]. Copanlisib was licensed in the U.S. for patients with
relapsed FL who have received ≥2 prior systemic therapies
[87]. Accelerated approval was based on the phase II
CHRONOS-1 trial in patients with indolent BCL (73% had FL)
relapsing after or refractory to ≥2 prior therapies and who
had received prior treatment with rituximab and an alkylating
agent [88]. After a median treatment duration of 6 months,
ORR was 60.6% in the full population and 58.7% in patients
with FL; overall median duration of response was 14.1 months,
and median PFS was 12.5 months [89]. The safety proﬁle dif-
fers from that of daily oral PI3K inhibitors, with low rates of
liver toxicity, colitis, pneumonitis, and opportunistic infections
[88, 89]. Unique toxicities associated with copanlisib included
transient hypertension and hyperglyemia. Phase III trials of
copanlisib in relapsed FL are ongoing, including in combination
with rituximab in patients relapsing after their last rituximab-
containing therapy (NCT02367040), and in combination with
chemoimmunotherapy (R-CHOP or bendamustine, rituximab
[BR]; NCT02626455) [90].
Duvelisib, an oral PI3K inhibitor targeting both the δ and
γ catalytic subunits, recently gained U.S. approval for
relapsed/refractory indolent BCL including FL after ≥2 prior
lines of therapy based on results of the phase II DYNAMO
trial [91, 92]. ORR was 46% and median PFS and OS were 8.4
and 18.4 months, respectively, among patients refractory to
both rituximab and alkylating chemotherapy [92]. Grade ≥ 3
AEs were seen, including neutropenia (28%), diarrhea (15%),
and infection (20%); 5% of patients had a fatal AE.
Early encouraging reports are emerging from the phase
III AUGMENT trial (NCT01938001), comparing rituximab and
lenalidomide (“R2”) with rituximab monotherapy in patients
with indolent NHL who were previously treated and had
rituximab-sensitve relapsed disease [93]. R2 was recently
reported to achieve improved PFS (39.4 vs. 14.1 months)
and ORR (78% vs. 53%; both p < .0001) compared with
rituximab alone, although no signiﬁcant OS beneﬁt is yet
seen at a median follow-up of 28.3 months.
Radioimmunotherapy (RIT) regimens, in which radioisotopes
are conjugated to antibodies (commonly, anti-CD20 agents),
have been used for the treatment of relapsed/refractory FL [2,
94]. Response rates of approximately 60% and median PFS and
OS of >4 years have been reportedwith RIT in patientswho have
received ≥1 prior therapy, with best responders those with mini-
mal bone marrow involvement and low tumor burden [95, 96].
RIT provides a valuable less toxic alternative for a select group of
patients, although complexities in delivery of this treatment and
availability of numerous competing agents have limited its wide-
spread adoption; currently, ibirtumomab tiuxetan is the only RIT
remaining on themarket for FL treatment [97].
Early Relapse
Patients with FL experiencing early relapse after initial therapy
are at high risk of poor outcomes. Currently, no single SOC exists
for patients with POD24, and therapeutic approaches are gener-
ally intensiﬁcation with standard agents or use of agents with
novel mechanisms of action compared with front-line therapy.
High-dose chemotherapy with autologous hematopoietic
stem cell transplantation (auto-HSCT) can prolong PFS and OS
and should be considered as consolidative therapy in early
relapse [2, 12, 98]. Few prospective data are available regarding
HSCT in the era of modern therapies, and its role continues to be
elucidated [2, 12]. Retrospective data suggest that patients with
POD24 beneﬁt from auto-HSCT (i.e., increased PFS and OS com-
pared with those not receiving transplant) [98–101]. A recent
study compared auto-HSCT with either matched-sibling donor
(MSD) or unrelated matched donor (UMD) allogeneic HSCT (allo-
HSCT) in patients with POD24 [102]. Findings suggest that out-
comes are similar with either autologous or allogeneic transplant
with MSD, whereas outcomes with UMD transplant were inferior,
largely because of higher transplant-related mortality. Currently,
allo-HSCT is largely restricted to ﬁt patients who cannot achieve
complete remission or have multiply relapsed disease.
In high-risk FL and early relapse after initial chemo-
immunotherapy, idelalisibwas studied ina retrospective
analysis of patients with POD24, with 59% of patients
achieving lymph-node responsewith idelalisib. TheORR
was57%anddidnotdiffer significantlywhetherpatients
had refractory or early relapsing disease (within 12 vs.
12–24 months) after initial therapy.
Data in early relapse are emerging for other agents and
are particularly important for transplant-ineligible patients. In
high-risk FL and early relapse after initial chemo-
immunotherapy, idelalisib was studied in a retrospective anal-
ysis of patients with POD24, with 59% of patients achieving
lymph-node response with idelalisib [103]. The ORR was 57%
and did not differ signiﬁcantly whether patients had refractory
or early relapsing disease (within 12 vs. 12–24 months) after
initial therapy. Lenalidomide is being investigated in the phase
III MAGNIFY trial in combination with rituximab in relapsed/
refractory NHL, including FL [104]. In patients with POD24,
the ORR was 48% compared with an ORR of 67% in all
patients with FL included in the study; 1-year PFS was 45%
and 66%, respectively. Recently, exploratory assessments from
the CHRONOS-1 trial of copanlisib in patients with relapsed/
refractory NHL who had received ≥2 prior therapies suggested
that ORR was similar between patients with FL with and with-
out POD24 (60.3% vs. 58.8%) [105]. Additionally, the ongoing
phase II SWOG 1608 study is evaluating obinutuzumab-based
therapeutic combinations in early-relapsing/refractory FL.
© 2019 The Authors.
The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
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Table 3. Unmet needs in follicular lymphoma
Unmet need Current practice
Areas of research and potential
solutions
Selecting the most appropriate
treatment for an individual
patient at a particular time
Identifying patients with limited
disease who are candidates for
radiation therapy versus rituximab
monotherapy or
chemoimmunotherapy regimens as
front-line management is not always
clear; it is not known whether
surveillance should be a management
option for these patients in the context
of the availability of active and
minimally toxic therapies.
Identifying therapies to manage
disease that is refractory to anti-CD20
regimens is difﬁcult, as the activity and
safety of investigational agents in this
setting has been limited.
Consensus is needed regarding how to
manage patients with high-risk disease.
Development of novel therapies in the
coming years should consider how to
tailor and optimize the beneﬁt-risk ratio
of therapies and regimens.
Determining predictive biomarkers of
progression, response, and resistance to
speciﬁc therapies will improve patient
selection for observation and
intervention.
Therapeutic strategies should be
developed to reduce the risk for
histologic transformation.
Availability of a clinically useful
tool to identify patients with
high-risk disease
Most prognostic tools do not guide
therapy; they are measured at
diagnoses and never measured again
during the disease course, as they have
not been validated in these later
settings.
Prospective validation, head-to-head
comparisons, and international
consensus for clinically useful tools to
identify patients with high-risk disease.
Potential integration of molecular,
clinical, and imaging parameters may be
required to deﬁne with improved
prognostic accuracy.
Speciﬁc genetic and epigenetic
aberrations in an individual
patient are not currently
accounted for in their
management
Therapies targeting molecular
alterations do not feature in the
current SOC.
A better understanding of disease
biology may reveal new therapeutic
avenues.
Targeted therapies, presently available
and in development, need to be
matched to individual disease biology.
Abbreviation: SOC, standard of care.
INVESTIGATIONAL THERAPIES
The armamentarium of treatment options is continually expan-
ding, with numerous novel therapies attempting to exploit spe-
ciﬁc biological vulnerabilities of FL. Enrollment in clinical trials
evaluating emerging therapies remains a high priority for
patients with relapsed/refractory FL requiring treatment, espe-
cially those who are refractory to both rituximab and alkylating
agents (double refractory). The following section summarizes
some of these emerging therapies (Table 2).
Drugs Targeting Epigenetic Modiﬁcation
A genetic hallmark of FL is the presence of mutations in
histone-modifying enzymes [106]. The gene for one such
enzyme, EZH2, is mutated in about 25% of cases [107]. Oral
inhibitors of EZH2 (e.g., tazemetostat, CPI-1205) are being
examined in phase II studies in FL, with early analyses
suggesting high response rates in EZH2-mutated disease
(ORR 82% for tazemetostat) [108, 109]. Several histone
deacetylase inhibitors are also undergoing clinical investiga-
tion in FL to address loss of histone acetylation associated
with CREBBP and EP300 mutations, including phase II trials
with panobinostat [90], mocetinostat [110], vorinostat
[110–112], and abexinostat [113].
Drugs Targeting Signaling Pathways
Chronic activation of B-cell receptor (BCR) signaling is critical
in FL progression, leading to activation of several signal trans-
duction pathways (e.g., NF-kB, PI3K-AKT) promoting prolifera-
tion and survival of malignant B cells [106]. Mutations in genes
encoding proteins in BCR pathways are also common [23, 24,
29–31]. In addition to PI3K already described, new PI3K inhibi-
tors are under development in FL, including umbralisib (which
also targets casein kinase-1ε) [114] and ME-401 [115].
Mutations in the BCR and NF-κB signaling pathway can
occur in patients with FL, affecting the caspase recruitment
domain-containing protein 11 (CARD11) commonly and Bruton
tyrosine kinase (BTK) infrequently [116]. Ibrutinib is a small-
molecule BTK inhibitor with effects on apoptosis, cellular adhe-
sion, migration, and the tumor microenvironment [117]. In the
phase II DAWN trial in relapsed/refractory FL, single-agent
ibrutinib did not meet the lower bound ORR threshold for the
primary endpoint (ORR 20.9%) [118]. Similar low ORR was
reported in another phase II trial of ibrutinib in recurrent FL
(37.5%), although interestingly, CARD11 mutations predicted
resistance to ibrutinib [119]. Given limited monotherapy activ-
ity, combination ibrutinib regimens in FL are being investi-
gated [90].
Drugs Targeting the Immune System
The programmed cell death-1 (PD-1) protein is widely
expressed and found on activated T cells, B cells, and natural
killer (NK) cells [120]. PD-1 binding to programmed death
ligand-1 and ligand-2 produces inhibitory signals leading to T-cell
apoptosis. Additionally, PD-1 inhibits antitumor cytotoxicity
through decreased NK cell-mediated killing. Inhibitors of the
PD-1 pathway (i.e., immune checkpoint inhibitors) are undergo-
ing clinical investigation in FL, including pembrolizumab [121],
nivolumab [90], and atezolizumab [122]. Although single-agent
© 2019 The Authors.
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activity appears limited in FL [123], there may be synergy with
other agents, including CD20 antibodies [124].
CD47 is a ubiquitously expressed penta-transmembrane
domain immunoglobulin-like protein that associates with
integrins and is a receptor for thrombospondin, an extracellular
matrix protein [125]. CD47 is also involved in the macrophage
interaction that inhibits phagocytosis, and is involved in several
biologic processes (e.g., motility, adhesion, and migration of
leukocytes, phagocytosis, recognition of “self”). Hu5F9-G4 is a
humanized antibody targeting CD47 that stimulates tumor
phagocytosis and antitumor responses [126], and results in a
phase I/IIb trial in relapsed/refactory FL have recently been
reported (ORR and CR of 71% and 43%, respectively, in the
seven patients in the FL cohort) [127].
Antibody-drug conjugates, designed to provide targeted
delivery of cytotoxic agents to antigen-expressing tumor cells,
are also being investigated in FL [128]. Phase I/II trials suggest
polatuzumab vedotin is active in FL in combination with
rituximab (ORR 75.0%) [90], in combination with rituximab
and bendamustine (ORR 100%) [129], and in combination
with obinutuzumab (ORR 78%) [130].
Another strategy for immune-based therapy is develop-
ment of biphenotypic antibodies that are able to bind to
malignant lymphocytes as well as engage and activate cyto-
toxic T cells [90, 129]. Mosunetuzumab is one such
biphenotypic antibody, with binding domains for both CD20
and CD3, and evaluation of the agent in FL is ongoing [131].
Additionally, tisagenlecleucel, an anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy in which autologous T cells are
gene-modiﬁed to carry antigen speciﬁcity for CD19, is licensed
for the treatment of relapsed/refractory high-grade B-cell lym-
phoma and DLBCL arising from FL based on results from a
single-arm clinical trial [132]. Tisagenlecleucel is under investi-
gation in a phase III trial in relapsed/refractory FL [90, 117].
Other CAR-T therapies undergoing clinical investigation in FL
include axicabtagene ciloleucel and JCAR017.
REMAINING UNMET NEEDS
• The protracted multiply relapsing clinical course of FL pre-
sents a fundamental challenge for how clinicians should best
balance treatment efﬁcacy, minimizing toxicity and preserv-
ing QoL.
• Although the armamentarium of FL therapies has
expanded, the optimal approach to selecting and sequenc-
ing treatments for an individual patient continues to be elu-
cidated (Table 3).
• Although several risk stratiﬁcation tools exist with new
models being developed, we continue to lack a clinically
useful tool that can accurately identify patients with
high-risk disease who may beneﬁt from individualized
management to achieve longer remission, prevent trans-
formation or resistance, and thereby further improve
clinical outcomes.
CONCLUSION
Signiﬁcant strides have been made in outcomes for patients
with FL. Our next priorities must tackle the subsets of patients
that are early progressors or multiply relapsed by deﬁning
optimum strategies to improve survival. Successfully achieving
this will require improved prognostication, understanding and
integration of the disease biology, and delineating molecular
determinants of response and resistance to existing and emer-
gent therapies. Most notably, POD24 has been shown to be a
powerful predictor of poor outcome, although it is not clear if
it can become a standard surrogate endpoint to evaluate efﬁ-
cacy of investigational treatments. Finally, current FL treat-
ment strategies are based on a “one size ﬁts all” approach;
speciﬁc genetic and epigenetic aberrations in an individual
patient are not currently accounted for in their management.
No genomic studies can be recommended currently with sufﬁ-
cient validation, although this is an area of ongoing investiga-
tion if we can identify biomarkers correlated with predictive
or prognostic value. In the future, a personalized approach to
treatment could help determine the most appropriate treat-
ment for an individual patient based on speciﬁc patient, clini-
cal, genetic, and epigenetic factors with our improved ability
to marry disease biology to therapy.
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